Improvement of therapeutic index of low-dose topotecan delivered per os

Annals of the New York Academy of Sciences

Volumn 922, Issue , 2000, Pages 330-333

  Pratesi, G ^a   De Cesare, M ^a   Zunino, F ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

TOPOTECAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; CANCER CHEMOTHERAPY; CANCER INHIBITION; CONFERENCE PAPER; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; LUNG NON SMALL CELL CANCER; MOUSE; NONHUMAN;

ANIMALIA;

EID: 0034502505     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2000.tb07057.x     Document Type: Conference Paper

References (4)

1. Topoisomerase I inhibitors: The relevance of prolonged exposure for present clinical development
2. Bioavailability and pharmacokinetics of oral topotecan: A new topoisomerase I inhibitor
3. A multicentre, randomised, phase III study of topotecan (T) administered intravenously or orally for advanced epithelial ovarian carcinoma
4. Effects of 5-FU and cis-DDP combination on human colorectal tumor xenografts